Volatile organic compounds in the exhaled breath of young patients with cystic fibrosis

被引:141
作者
Barker, M
Hengst, M
Schmid, J
Buers, HJ
Mittermaier, B
Klemp, D
Koppman, R
机构
[1] Univ Technol Aachen, Med Ctr, Dept Paediat, Aachen, Germany
[2] Res Ctr Julich, Inst Chem & Dynam Geospere, Div Troposhere 2, Julich, Germany
[3] Res Ctr Julich, Cent Lib, Julich, Germany
关键词
biological markers; breath tests; cystic fibrosis; gas chromatography;
D O I
10.1183/09031936.06.00085105
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Inflammatory mediators in the exhaled breath are receiving growing medical interest as noninvasive disease markers. Volatile organic compounds have been investigated in this context, but clinical information and methodological standards are limited. The levels of ethane, propane, n-pentane, methanol, ethanol, 2-propanol, acetone, isoprene, benzene, toluene, dimethyl sulphide (DMS) and limonene were measured in repeated breath samples from 20 cystic fibrosis patients and 20 healthy controls (aged 8-29 yrs). Three end-exhaled and one ambient air sample were collected per person and analysed on a customised gas chromatography system. Intra-subject coefficients of variation ranged between 9 and 34%, and hydrocarbon breath levels were influenced by their inspired concentrations. The alveolar gradient for pentane was higher in cystic fibrosis patients than in healthy controls (0.36 versus 0.21 ppb) and inversely proportional to forced expiratory volume in one second; highest values were observed in patients with pulmonary exacerbations (0.73 versus 0.24 ppb). Cystic fibrosis patients also exhibited a lower output of DMS (3.9 versus 7.6 ppb). Group differences were not significant for ethane and the remaining substances. It was concluded that chemical breath analysis for volatile organic compounds is feasible and may hold potential for the noninvasive diagnosis and follow-up of inflammatory processes in cystic fibrosis lung disease.
引用
收藏
页码:929 / 936
页数:8
相关论文
共 32 条
[1]  
BILTON D, 1990, CLIN SCI, V79, pP20
[2]   CYSTIC-FIBROSIS, BREATH PENTANE, AND LIPID-PEROXIDATION [J].
BILTON, D ;
MADDISON, J ;
WEBB, AK ;
SEABRA, L ;
JONES, M ;
BRAGANZA, JM .
LANCET, 1991, 337 (8754) :1420-1420
[3]   New concepts of the pathogenesis of cystic fibrosis lung disease [J].
Boucher, RC .
EUROPEAN RESPIRATORY JOURNAL, 2004, 23 (01) :146-158
[4]   Potential for antioxidant therapy of cystic fibrosis [J].
Cantin, AM .
CURRENT OPINION IN PULMONARY MEDICINE, 2004, 10 (06) :531-536
[5]   Effects of ventilation on the collection of exhaled breath in humans [J].
Cope, KA ;
Watson, MT ;
Foster, WM ;
Sehnert, SS ;
Risby, TH .
JOURNAL OF APPLIED PHYSIOLOGY, 2004, 96 (04) :1371-1379
[6]  
Courtney J M, 2004, J Cyst Fibros, V3, P223, DOI 10.1016/j.jcf.2004.06.006
[7]  
Euler DE, 1996, CLIN CHEM, V42, P303
[8]   Breath isoprene: Temporal changes in respiratory output after exposure to ozone [J].
Foster, WM ;
Jiang, L ;
Stetkiewicz, PT ;
Risby, TH .
JOURNAL OF APPLIED PHYSIOLOGY, 1996, 80 (02) :706-710
[9]   LIMONENE IN EXPIRED LUNG AIR OF PATIENTS WITH LIVER-DISEASE [J].
FRIEDMAN, MI ;
PRETI, G ;
DEEMS, RO ;
FRIEDMAN, LS ;
MUNOZ, SJ ;
MADDREY, WC .
DIGESTIVE DISEASES AND SCIENCES, 1994, 39 (08) :1672-1676
[10]   INTRAVENOUS CYSTEAMINE THERAPY FOR NEPHROPATHIC CYSTINOSIS [J].
GAHL, WA ;
INGELFINGER, J ;
MOHAN, P ;
BERNARDINI, I ;
HYMAN, PE ;
TANGERMAN, A .
PEDIATRIC RESEARCH, 1995, 38 (04) :579-584